Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound Hypotensive Tablets, also known as Beijing Hypotensive No. 0, is a fixed-dose combination pharmaceutical drug used for the treatment of mild to moderate essential hypertension. It combines five active ingredients: reserpine, hydrochlorothiazide, triamterene, dihydralazine sulfate, and chlordiazepoxide. This multi-component approach targets various physiological pathways involved in blood pressure regulation, offering a synergistic hypotensive effect. The drug is recognized for its efficacy, affordability, and long-standing use in China for hypertension management.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Compound Hypotensive Tablets.